OSTEOPOROSIS AND TREATMENT SIDE-EFFECTS * Jaw Osteonecrosis

THE GOOGLE SEARCH FOR FOSAMAX AND OTHERS BRINGS FORWARD MANY PAID ADVERTISING LAW FIRMS REGARDING LAWSUIT INVITATION AND CONSULTATION REGARDING THIS CONCERN.

WWW.CASTMD.COM LOOKED TO SEE IF THIS IS A PROBABILITY OR POSSIBILITY FOR LITIGATION AND JURY AWARD.  WHAT DOES SOME OF THE LITERATURE SAY? 

MANY COMMENTS ARE BEING MADE OF THE RISK OF TAKING OSTEOPOROSIS MEDICATION FOR PREVENTING BONE LOSS, AND REBUILDING BONE.  MOST, IF NOT ALL OF THE CONTROVERSY IS RELATED TO JAW BONE LOSS, OSTEONECROSIS OF THE JAW.  THE CONTROVERSY ALSO RELATES TO THE POSSIBILITY OF THE MEDICINES CALLED "BIPHOSPHONATES" SUCH AS FOSAMAX, AREDIA, AND ZOMETA, AND POSSIBLY OTHERS.

OSTEONECROSIS OF THE JAW IS A DEVASTATING CONDITION.  THE BONE LOOKS AND ACTS INFECTED.  MOST CASES COME FROM THE ILL EFFECTS OF INFECTION DUE TO DENTAL PROBLEMS OR DENTAL SURGERIES.  MANY CASES, IF NOT ALMOST ALL, COME FROM THE USE OF INTRAVENOUS USE OF THE MEDICINES, WITH CASES OF METASTATIC BONE CANCER.

MERCK PUBLISHED THEIR CONTROLLED TRIALS OF OVER 17,000 PATIENTS, WITH 10 YEARS' DATA USING FOSAMAX, SHOWING NO REPORTS OF ONJ.  IN POST-MARKETING USE, MERCK ESTIMATES BY MARCH 31, 2006 THE CUMMULATIVE RISK FROM ALL SOURCES OF CAUSE WAS ESTIMATED AT LESS THAN 1/100,000 PATIENT-TREATMENT YEARS.

CURRENTLY, THE NATIONAL OSTEOPOROSIS FOUNDATION SEES THE RISK AS RARE IN PERSONS TAKING ANY ORAL FORM OF THE MEDICINE FOR OSTEOPOROSIS.  THE FOUNDATION ALSO STATES THAT IT BELIEVES THAT THE RISK OF FRACTURES AND BONE LOSS IS MUCH GREATER TO MOST PATIENTS THAN ANY RISK OF DEVELOPING THE ONJ PROBLEM DUE TO THE MEDICINES FOR OSTEOPOROSIS. 

PLEASE, IF YOU ARE ON A MEDICINE FOR REDUCTION OF OSTEOPOROSIS RISK, A BIPHOSPHONATE, TALK WITH YOUR DOCTOR AND STAY INFORMED.  HOPEFULLY THIS HAS ASSISTED YOU IN YOUR DECISION TO BE AND STAY HEALTHY.Cool

THE PRESTIGIOUS NEW ENGLAND JNL OF MED WILL SPEAK TO THE ISSUE THIS NEXT WEEK, I AM ANTICIPATING.

 

Leave a Reply

You must be logged in to post a comment.